Skip to main content
. Author manuscript; available in PMC: 2015 Aug 12.
Published in final edited form as: Pediatr Blood Cancer. 2013 Aug 31;61(2):238–244. doi: 10.1002/pbc.24686

Table III.

Pharmacodynamic Parameters for TNF-alpha and IL-6 after Mifamurtide Infusion

Marker Mifamurtide Infusion duration, min aMean (%CV) bEmax (pg/mL) Mean (%CV) cAUEC0-tlast (hr.pg/ml) Median (range) TEmax (hr)
dTNF-alpha 60 412 (105) 2460 (82.1) 4.00 (2.00–4.00)
30 582 (96.9) 2260 (86.0) 2.05 (1.00–4.00)
eIL-6 60 895 (94.1) 4650 (177) 4.00 (2.00–4.08)
30 811 (112.0) 2200 (174) 4.00 (2.00–4.08)
a

%CV: coefficient of variation;

b

Emax: maximum pharmacodynamic effect;

c

AUEC0-tlast: area under the effect the time curve from time 0 to time of last quantifiable effect;

d

TNF-alpha: tumor necrosis factor alpha;

e

IL-6: interleukin-6